Clinical trial NCT05858710: Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma
Official title: Phase I Dose Escalation Study of 3-Weekly Intravenous DPPG2-TSL-DOX Combined With Regional Hyperthermia in Locally Advanced or Metastatic Soft Tissue Sarcoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Sarcoma, Soft Tissue
Keywords: Sarcoma, Soft Tissue
Doxorubicin/ IV + Liposomes
Doxorubicin
Lead sponsor: Thermosome GmbH
Sponsor class: INDUSTRY
First posted: 2023-05-15
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: an adapted 3+3 multiple ascending dose (MAD) design with sentinel dosing
Primary purpose: TREATMENT

Brief summary: This study aims to explore a new therapeutic approach for advanced soft tissue sarcoma (STS) by investigating the safety, tolerability, and maximum tolerable dose (MTD) of DPPG2-TSL-DOX combined with regional hyperthermia (RHT) in patients who have been pre-treated with anthracycline, e.g. doxorubicin (DOX).

Detailed description: Considering that up to 40 percentage of patients with soft tissue sarcoma (STS) will develop metastatic disease and that for these patients overall survival (OS) ranges between 3.7 to 25 months it becomes clear that new therapeutic approaches for the treatment of advanced STS are urgently needed. Doxorubicin (DOX) is a cytotoxic compound that belongs to the class of anthracyclines. DOX has had market authorization since 1960s and is considered the most active chemotherapeutic drug for the treatment of STS. DPPG2-TSL-DOX is a novel formulation of DOX encapsulated in DPPG2-containing thermosensitive liposomes (TSL). Regional hyperthermia (RHT) with a tumor target temperature of ≥41.5 to ≤44 degree of Celsius combined with anthracycline-based chemotherapy has shown to improve survival in patients with localized high-risk STS. Treatment with DPPG2-TSL-DOX aims at combining the confirmed anti-tumor efficacy of anthracyclines in the treatment of locally advanced STS with RHT-triggered DOX release from circulating liposomes resulting in higher local DOX concentrations in the tumor as observed in preclinical studies.

DPPG2-TSL-DOX combined with RHT has been investigated in feline sarcoma at 1 mg/kg dose level resembling the clinically recommended dose level of standard DOX with considerably improved efficacy and better tolerability. The proposed study will characterize the safety and tolerability and, if applicable, the maximum tolerable dose (MTD) of DPPG2-TSL-DOX in combination with RHT in patients with advanced or metastatic STS who have been pre-treated with anthracycline. An adapted 3+3 MAD study design with sentinel dosing and a starting dose of 20 mg/m\^2 DPPG2-TSL-DOX is applied in this study to identify dose-limiting toxicities (DLTs) of DPPG2-TSL-DOX in combination with RHT.

Eligibility criteria: Inclusion criteria

1. Age at the time of consent ≥18 years.
2. Patient has provided written informed consent prior to any study-specific procedure.
3. Locally advanced (unresectable) or metastatic STS, including histological sarcoma subtypes treated as STS, for which treatment with DOX monotherapy is appropriate, as confirmed by the investigator.
4. Pretreatment with an anthracycline (including DOX, epirubicin as mono- or combination therapy). Patients who received anthracycline in an adjuvant setting are eligible.
5. Progressive disease not suitable for surgery after

   1. only one further line of chemotherapy (including TKI) if the RHT field targets the clinically relevant tumor manifestation/s (e.g., locally advanced or multifocal intraabdominal STS; diffuse metastatic STS in which RHT of a tumor manifestation \[e.g., liver\] is considered relevant although other systemic metastases are present that do not endanger the patient, as per the judgment of the investigator), or
   2. two or more further lines of chemotherapies (including TKI) for patients with metastatic STS and a tumor manifestation suitable for RHT.
6. All previous oncological treatments must have been completed ≥3 weeks (21 days) prior to the first dose of study treatment, ensuring a sufficient washout period.
7. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer et al. 2009).
8. Tumor accessible for RHT.
9. Left ventricular ejection fraction (LVEF) \>50% (within 28 days prior to enrolment).
10. Adequate hematologic, organ and coagulation function within 14 days prior to enrolment as assessed by local lab:

    1. Absolute neutrophil count (ANC) ≥1.5×10\^9/L. Granulocyte-colony stimulating factor (G-CSF) cannot be administered within 2 weeks (14 days) prior to enrolment.
    2. Platelet count ≥100×10\^9/L.
    3. Hemoglobin ≥9.0 g/dL. No transfusions are allowed within 2 weeks (14 days) prior to enrolment.
    4. Serum creatinine ≤1.5 times upper limit of normal (ULN).
    5. Negative dipstick for proteinuria or if proteinuria ≥2+ (equals ≥ 1001 mg/L or 1.001 g/L (Lamb, et al., 2009), then additional 24 h urine collection \<1g protein/ 24 h.
    6. Total bilirubin within ULN (except for patients with Gilbert's syndrome, who must have a total bilirubin \<3 mg/dL).
    7. ALT/ AST ≤3.0×ULN; if the liver has tumor involvement, AST and ALT ≤5.0×ULN are acceptable.
    8. An adequate coagulation function as defined by international normalized ratio (INR) ≤1.5×ULN or prothrombin time ≤1.5×ULN, and partial thromboplastin time ≤1.5×ULN (unless receiving anticoagulant therapy). Patients receiving phenprocoumon are recommended to switch to low molecular weight heparin and should have achieved stable coagulation status prior to the first dose of study treatment.
11. Tubular excretion rate (TER) by MAG-3-clearance ≥ TERLoLi (TERLoLi = 70% TERNorm).
12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Appendix 1).
13. If female, must:

    1. Be not of child-bearing potential due to surgical sterilization (at least 6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history or menopause.
    2. Be a post-menopausal woman, defined as a woman meeting either of the following criteria:

    i. spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin-releasing hormone, antiestrogens, selective estrogen receptor modulators \[SERMs\], or chemotherapy) ii. spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone level \>40 mIU/mL.
14. Women of childbearing potential (WOCBP; for a definition see Appendix 2) and men able to father a child must be ready and able to use two medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at screening, during trial participation, and until 6 months after last dose of study treatment. Also, partner of male participants, who is of childbearing potential must use a highly effective method of contraception during the same duration (Please refer to Appendix 2 for methods of highly effective contraception). A list of contraception methods meeting these criteria is provided in the patient information.
15. At least 3 months' life expectancy in the investigator's assessment.

Exclusion criteria

1. Patients already enrolled in any clinical study involving an investigational product or medical device or have participated within the past 30 days in a clinical trial involving an investigational product or medical device.
2. History of another primary malignancy, with the exception of:

   1. curatively treated non-melanomatous skin cancer
   2. curatively treated cervical carcinoma in situ
   3. non-metastatic prostate cancer, or
   4. other primary non-hematologic malignancies that had been treated with curative intent, no known active disease, and no treatment administered during the last 3 years prior to enrolment that the investigator agrees will not affect the interpretation of study results or would be unsuitable for participation in the study.
3. Active fungal, bacterial and/or known viral infection including human immunodeficiency virus or viral (A, B, or C) hepatitis.
4. Resting heart rate of \>100 bpm (measured after ≥10 min. in seated position). Note: If \>100 bpm, the measurement should be repeated by up to 3 consecutive measurements at least 10 minutes apart from each other. If all 3 measurements are \>100 bpm the exclusion criterion is met.
5. Uncontrolled intercurrent illness including, but not limited to, an ongoing/active infection requiring parenteral antibiotics.
6. Have a serious cardiac condition, such as:

   1. unstable angina pectoris
   2. angioplasty, cardiac stenting, or myocardial infarction within 6 months of enrolment
   3. valvulopathy that is severe, moderate, or deemed clinically significant
   4. arrhythmias that are symptomatic or require treatment
7. Have a QTcF interval of \>450 msec for males and \>470 msec for females on screening electrocardiogram (ECG) utilizing Fridericia's correction.
8. Psychiatric illness or social situation that would limit compliance with study requirements.
9. Any planned or required major surgery during the course of the study.
10. Pregnant or breastfeeding female.
11. Individuals who are institutionalized on a judicial or regulatory order.

Primary outcomes:
measure: Maximum tolerated dose (MTD)
timeFrame: End of study (up to 14 months)
Secondary outcomes:
measure: Adverse Events (AEs)
timeFrame: End of study (up to 14 months)
measure: Serious Adverse Events (SAEs)
timeFrame: End of study (up to 14 months)
measure: Laboratory abnormalities
timeFrame: End of study (up to 14 months)
measure: Electrocardiogram (ECG) abnormalities
timeFrame: End of study (up to 14 months)
measure: Echocardiogram (ECHO) abnormalities
timeFrame: End of study (up to 14 months)
measure: Renal toxicities
timeFrame: End of study (up to 14 months)
measure: Maximum concentration (Cmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Last measurable (non-zero) concentration (Clast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Area under the curve from time 0 to x hours (AUC[0-x] ) after the start of infusion of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Area under the curve from time 0 to the time of the last quantifiable concentration (AUC[0-tlast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Time of maximum observed concentration (Tmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Terminal half-life (T½) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Clearance (CL) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Volume of distribution at steady-state (Vss) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Maximum concentration obtained after administration (Cmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Last measurable (non-zero) concentration (Clast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Area under the curve from time 0 to x hours (AUC[0-x] ) after the start of infusion of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Area under the curve from time 0 to the time of the last quantifiable concentration (AUC[0-tlast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Time of maximum observed concentration (Tmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Terminal half-life (T½) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Clearance (CL) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
measure: Volume of distribution at steady-state (Vss) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX
timeFrame: End of study (upto 14 months)
Other outcomes:
measure: Radiographic response
timeFrame: day 64 (+/-3) in the study for each participant and end of study (21 [+7] days after last study drug treatment)
measure: Radiographic local response
timeFrame: day 64 (+/-3) in the study for each participant and end of study (21 [+7] days after last study drug treatment)
measure: Tumor temperatures (optional)
timeFrame: day 23, 44, 65, 86, 107 (+/-3) in the study for each participant
Locations:
city: Berlin
country: Germany
facility: Helios Klinikum Berlin-Buch GmbH
city: Munich
country: Germany
facility: Klinikum der Universität München (KUM) Campus Großhadern
Study officials:
affiliation: Helios Klinikum Berlin-Buch GmbH
name: Peter Reichardt, PD Dr.
role: PRINCIPAL_INVESTIGATOR
References: